|View printer-friendly version|
|March 13, 2002 4:11 p.m.|
|Teva Announces Federal Judge Invalidates Augmentin Patents|
Jerusalem, Israel, March 13, 2002 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced today that a federal judge has ruled in its favor, invalidating three GlaxoSmithKline patents, otherwise due to expire in 2017, covering the antibiotic Augmentin. The ruling follows an earlier decision by the same court on December 14, 2001 that invalidated a fourth GlaxoSmithKline patent otherwise scheduled to expire in 2018. GlaxoSmithKline's remaining three patents concerning Augmentin will expire by December 24, 2002. Teva's challenge to those three remaining patents is set for trial in May 2002.